Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

This trial is testing a combination of VG161 (an experimental virus-based therapy injected directly into tumors) plus nivolumab (a standard immunotherapy drug) for people with advanced or metastatic stomach or gastroesophageal cancer that has stopped responding to prior treatments, including immunotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced stomach or gastroesophageal junction cancer - You have already tried and failed at least two treatment regimens, including an anti-PD-1 immunotherapy drug - You have at least one tumor large enough to inject (over 1.5 cm) that can be reached with ultrasound guidance - You have tested positive for herpes simplex virus type 1 (HSV-1) antibodies - You are in reasonably good health (ECOG 0–1) **You may NOT be eligible if...** - You have uncontrolled or untreated brain metastases - Your organ function (liver, kidneys, heart) is significantly impaired - You are pregnant or breastfeeding - You have active serious infections or autoimmune conditions Talk to your doctor to see if this trial is right for you.